Recombinant human growth hormone therapy in autosomal recessive polycystic kidney disease

被引:0
|
作者
Marusia Lilova
Bernard S. Kaplan
Kevin E. C. Meyers
机构
[1] The Children's Hospital of Philadelphia,Division of Nephrology and Department of Pediatrics
[2] The Children's Hospital of Philadelphia,Division of Nephrology
[3] University of Pennsylvania,undefined
来源
Pediatric Nephrology | 2003年 / 18卷
关键词
Autosomal recessive polycystic kidney disease; Growth hormone; Growth; Chronic renal failure;
D O I
暂无
中图分类号
学科分类号
摘要
Patients with autosomal recessive polycystic kidney disease (ARPKD) may have growth retardation that is disproportionate to the degree of renal dysfunction. We treated growth-retarded ARPKD patients with recombinant growth hormone (rhGH) and document the response to therapy and effect of rhGH on the rate of progression of renal failure. The diagnosis of ARPKD and congenital hepatic fibrosis was made on the basis of clinical findings and by abdominal ultrasound examinations. Seventeen patients (6 girls/11 boys) aged 0.3–18.3 years were studied. Diagnosis was made prenatally in 6, after birth in 3, and in 8 between 0.33 and 10 years. Follow-up was 2 months to 14.3 years (median 6.9 years). Growth, growth velocity, weight, and bone age were measured before and after treatment with rhGH. Insulin-like growth factor-1 and IGF binding protein 3 were measured prior to rhGH therapy. Five children (1 girl/4 boys) with height Z-scores ≤1.2 (5/17) aged 4.5–11.9 years received rhGH therapy. Duration of rhGH therapy was 0.3–5.4 years. All responded to rhGH (Z-score before –2.8 vs. –1.26 after treatment, P=0.03). An increase in height Z-score was noted 0.5–1.5 years after starting rhGH therapy. There were no side effects from rhGH therapy. The initial Z-score in the untreated group was –0.35 and the final score was –0.64. Initial glomerular filtration rate (GFR) in the treated group was 77 versus 104 ml/min per 1.73 m2 in the non−treated group. GFR in 3 of 6 growth-retarded patients (<5th percentile) was 38, 65, and 30 ml/min per 1.73 m2. GFR in 2 of 11 non-growth-retarded patients was 30 and 26 ml/min per 1.73 m2. The change from initial GFR and final GFR in treated patients was 77 versus 76 ml/min per 1.73 m2, and non−treated patients 104 versus 89 ml/min per 1.73 m2 (P>0.05). Growth failure in ARPKD may be attributable to factors other than chronic renal insufficiency alone. Use of rhGH therapy in ARPKD is safe, effective, and has the potential to improve the physical and psychological well-being of these children.
引用
收藏
页码:57 / 61
页数:4
相关论文
共 50 条
  • [41] The genetics of Autosomal Recessive Polycystic Kidney Disease (ARPKD)
    Goggolidou, Paraskevi
    Richards, Taylor
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2022, 1868 (04):
  • [42] Autosomal Recessive Polycystic Kidney Disease with Caroli Syndrome
    Obusez, Emmanuel C.
    Udayasankar, Unni
    JOURNAL OF UROLOGY, 2015, 193 (02): : 679 - 680
  • [43] AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY-DISEASE (ARPCKD)
    KAPLAN, BS
    FAY, J
    SHAH, V
    DILLON, MJ
    BARRATT, TM
    CLINICAL AND INVESTIGATIVE MEDICINE-MEDECINE CLINIQUE ET EXPERIMENTALE, 1987, 10 (04): : A66 - A66
  • [44] Molecular genetics of autosomal recessive polycystic kidney disease
    Harris, PC
    Rossetti, S
    MOLECULAR GENETICS AND METABOLISM, 2004, 81 (02) : 75 - 85
  • [45] Autosomal Recessive Polycystic Kidney Disease: Not just a Renal Disease
    Rohatgi, Sarika
    Sweeney, William E.
    Schwasinger, Emma
    Kampa, Nicholas
    Avner, Ellis D.
    HEPATOLOGY, 2015, 62 : 1046A - 1046A
  • [46] Proximal tubular cysts in fetal human autosomal recessive polycystic kidney disease
    Nakanishi, K
    Sweeney, WE
    Zerres, K
    Guay-Woodford, LM
    Avner, ED
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2000, 11 (04): : 760 - 763
  • [47] The mTOR Pathway Is Activated in Human Autosomal-Recessive Polycystic Kidney Disease
    Becker, Jan Ulrich
    Saez, Anabelle Opazo
    Zerres, Klaus
    Witzke, Oliver
    Hoyer, Peter Friedrich
    Schmid, Kurt Werner
    Kribben, Andreas
    Bergmann, Carsten
    Nuernberger, Jens
    KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (02): : 129 - 138
  • [48] A Potential Therapy Using Antisense Oligonucleotides to Treat Autosomal Recessive Polycystic Kidney Disease
    Li, Huixia
    Wang, Chunli
    Che, Ruochen
    Zheng, Bixia
    Zhou, Wei
    Huang, Songming
    Jia, Zhanjun
    Zhang, Aihua
    Zhao, Fei
    Ding, Guixia
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (04)
  • [49] Functional activity of epidermal growth factor receptors in autosomal recessive polycystic kidney disease
    Sweeney, WE
    Avner, ED
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 1998, 275 (03) : F387 - F394
  • [50] AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY IN RATS
    INAGE, Z
    KIKKAWA, Y
    MINATO, M
    OWADA, M
    KITAGAWA, T
    OHNO, K
    KONDO, K
    UEDA, Y
    IIDAKA, K
    NEPHRON, 1991, 59 (04): : 637 - 640